GSK Press Releases - EIN Presswire - Press Release Distribution Service

Published on June 27, 2013 - 15:26 GMT

GlaxoSmithKline’s drisapersen (previously GSK2402968/PRO051) to receive Food and Drug Administration Breakthrough Therapy ...

Issued: Thursday 27 June 2013, London UK GlaxoSmithKline plc (GSK) received verbal notification yesterday that its investigational compound drisapersen (previously GSK2402968/PRO051) has been granted Breakthrough Therapy designation by the United States …

Distribution channels: Companies

Published on June 27, 2013 - 10:18 GMT

GSK and Save the Children launch $1 million award to discover new healthcare innovations for reducing child deaths

- The Healthcare Innovation Award is the first joint initiative announced following the launch of an ambitious new partnership between GSK and Save the Children which aims to save the lives of a million of the world’s poorest children. Issued: Thursday 27 …

Distribution channels: Companies

Published on June 24, 2013 - 10:26 GMT

GSK announces data from five Phase III studies of albiglutide, an investigational once-weekly treatment for type 2 diabetes

Issued: Monday 24 June 2013, London UK Data from five long-term Phase III studies (Harmony 1 to 5) comparing albiglutide, an investigational glucagon-like peptide receptor agonist (GLP-1), to placebo and a range of active comparators were presented at the …

Distribution channels: Companies

Published on June 18, 2013 - 12:07 GMT

GSK receives offer for its thrombosis brands and related manufacturing site

Issued: Tuesday 18 June 2013, London UK GlaxoSmithKline (LSE: GSK) has today received an offer for its thrombosis brands and Notre-Dame de Bondeville (NDB) site from Aspen Global Incorporated and Aspen Pharmacare Holdings Limited. A period of exclusivity …

Distribution channels: Companies

Published on June 10, 2013 - 22:43 GMT

GSK statement regarding 2010 Nature Medicine study

June 10, 2013 GSK and Nature Medicine both received some weeks ago the same information alleging misrepresentation of data in a research paper written by scientists at GSK’s China research centre and published in Nature Medicine in 2010. The published …

Distribution channels: Companies

Published on June 6, 2013 - 21:18 GMT

GSK statement in response to FDA Advisory Committee’s vote on availability of Avandia (rosiglitazone)

Issued: June 6, 2013, Philadelphia, PA GlaxoSmithKline [NYSE: GSK] confirmed today that a joint advisory committee to the U.S. Food and Drug Administration (FDA) voted to continue to make Avandia (rosiglitazone) available to appropriate patients with the …

Distribution channels: Companies

Published on June 3, 2013 - 11:51 GMT

GSK announces Phase III data for TYKERB/TYVERB® (lapatinib) in combination with chemotherapy for advanced HER2-positive gastric ...

Issued: Monday 3 June 2013, London UK GlaxoSmithKline (GSK) plc today announced that its study of TYKERB/TYVERB® (lapatinib) in combination with chemotherapy in patients with HER2-positive advanced gastric cancer did not meet the primary endpoint of …

Distribution channels: Companies

Published on June 1, 2013 - 13:12 GMT

GSK announces late-stage clinical data for VOTRIENT® (pazopanib) following chemotherapy in women with advanced epithelial ovarian ...

Issued 1 June 2013, London UK Treatment with VOTRIENT following chemotherapy reduced risk of disease progression GlaxoSmithKline (GSK) plc today announced that its Phase III clinical trial of VOTRIENT (pazopanib) as maintenance therapy in women with …

Distribution channels: Companies

Published on May 29, 2013 - 22:36 GMT

Two new GSK oral oncology treatments, BRAF-inhibitor Tafinlar® (dabrafenib) capsules and the first MEK-inhibitor Mekinist™ (...

Issued: 29 May 2013, London, UK and Philadelphia, U.S. - Both approved for unresectable or metastatic melanoma with BRAF V600E mutation; Mekinist also approved for BRAF V600K mutation GlaxoSmithKline plc [LSE/NYSE: GSK] announced today that the U.S. Food …

Distribution channels: Companies

Published on May 29, 2013 - 19:10 GMT

GSK and Genmab announce positive top-line results from pivotal trial of ARZERRA® (ofatumumab) combined with chlorambucil in ...

Issued:Wednesday 29 May 2013, London UK GlaxoSmithKline (GSK) plc and Genmab A/S (OMX: GEN) announced today that their Phase III study of ARZERRA® (ofatumumab) in combination with chlorambucil versus chlorambucil alone in patients with previously untreated …

Distribution channels: Companies

Published on May 29, 2013 - 11:03 GMT

GSK strengthens vaccines business with acquisition of Okairos

-GSK to further expand its vaccines platform technology expertise through strategic acquisition Issued: Wednesday 29 May 2013, London UK GlaxoSmithKline (GSK) today announced that it has acquired Okairos AG (Okairos), a specialist developer of vaccine …

Distribution channels: Companies

Published on May 24, 2013 - 10:39 GMT

Grant to Help Coordinate Campaign to Train One Million Community Health Workers in sub-Saharan Africa

Issued: Friday 24 May 2013, London UK Addis Ababa, Ethiopia In an effort to broadly expand the reach of health care services in sub-Saharan Africa, GlaxoSmithKline (GSK) will contribute $750,000 to the One Million Community Health Workers Campaign. …

Distribution channels: Companies

Published on May 22, 2013 - 11:52 GMT

GlaxoSmithKline awarded up to $200 million by U.S. government to develop new antibiotics

- Award is first of its kind public-private partnership with Biomedical Advanced Research and Development Authority - Funding will support development of drugs to fight antibiotic resistance and bioterrorism Issued: Wednesday 22 May 2013, London UK and …

Distribution channels: Companies

Published on May 13, 2013 - 19:00 GMT

Regulatory update: Trametinib US PDUFA date extended to 3 September 2013

Issued: 1 May 2013, London UK GSK today announced that the US Prescription Drug User Fee Act (PDUFA) goal date for trametinib, its MEK inhibitor, has been extended by 3 months to 3 September 2013. The company recently submitted additional manufacturing …

Distribution channels: Companies

Published on May 13, 2013 - 18:59 GMT

Funding boost for GSK’s open innovation research into diseases affecting the developing world

Issued: Friday 3 May 2013, London UK GlaxoSmithKline plc (GSK) today announced a funding injection of up to £5m from the Wellcome Trust to support its open approach to discovering and developing urgently needed new treatments for diseases of the developing …

Distribution channels: Companies

Published on May 13, 2013 - 18:59 GMT

GSK gives update on plans to share detailed clinical trial data as part of its commitment to transparency

-New online system will enable researchers to request access to patient level data from GSK clinical trials to help further scientific understanding and improve patient care -Panel of independent experts will review research proposals for access to …

Distribution channels: Companies

Published on May 13, 2013 - 18:59 GMT

GSK enters new commitment with the GAVI Alliance to supply cervical cancer vaccine for girls in the world’s poorest countries

Issued: Thursday 9 May 2013, London UK GlaxoSmithKline (GSK) today announced a new commitment to the GAVI Alliance to supply its cervical cancer vaccine as part of a newlong termprogramme to help protect girls against cervical cancer in the world’s poorest …

Distribution channels: Companies

Published on May 13, 2013 - 18:59 GMT

GSK and Save the Children form unique partnership to save the lives of one million children

- Working together to accelerate the availability of two children’s medicines and establishing a joint RD board to tackle causes of newborn and infant death - The partnership will initially run two flagship programmes in Sub Saharan Africa – Democratic …

Distribution channels: Companies

Published on May 13, 2013 - 18:59 GMT

BREO™ ELLIPTA™ gains US approval for the treatment of COPD

Issued: Friday 10 May 2013, London UK and South San Francisco, CA, USA – LSE Announcement GlaxoSmithKline plc (LSE/NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the US Food and Drug Administration (FDA) has approved BREO™ ELLIPTA™ as …

Distribution channels: Companies

Published on April 30, 2013 - 13:33 GMT

GSK announces regulatory submission for umeclidinium monotherapy in US

Issued: Tuesday 30 April 2013, London UK – LSE Announcement GlaxoSmithKline plc (LSE:GSK) today announced the submission of a regulatory application in the US for the investigational once-daily medicine, umeclidinium bromide (UMEC), for patients with …

Distribution channels: Companies